证券代码：688382 证券简称：益方生物 益方生物科技（上海）股份有限公司 2025 年第二次临时股东会会议资料 二〇二五年十二月 | | | | 的议案 31 | | --- | | 议案十二 | 关于确定公司董事会董事类型的议案 32 | | --- | --- | | 议案十三 | 关于修订公司部分内部治理制度的议案 33 | 3 益方生物科技（上海）股份有限公司 2025 年第二次临时股东会会议须知 4 六、股东及股东代理人要求发言或提问时，不得打断会议报告人的报告或其 他股东及股东代理人的发言。在股东会进行表决时，股东及股东代理人不再进行 发言。股东及股东代理人违反上述规定，会议主持人有权加以拒绝或制止； 七、主持人可安排公司董事、高级管理人员等回答股东所提问题。对于可能 将泄露公司商业秘密及/或内幕信息，损害公司、股东共同利益的提问，主持人 或其指定的有关人员有权拒绝回答； 八、出席股东会的股东及股东代理人，应当对提交表决的议案发表如下意见 之一：同意、反对或弃权。现场出席的股东请务必在表决票上签署股东名称或姓 名。未填、错填、字迹无法辨认的表决票、未投的表决票均视投票人放弃表决权 利，其所持股 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-049 益方生物科技（上海）股份有限公司 第二届董事会 2025 年第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、审议通过《关于<益方生物科技（上海）股份有限公司 2025 年限制性 股票激励计划（草案）>及其摘要的议案》 同意公司制定的《益方生物科技（上海）股份有限公司 2025 年限制性股票 激励计划（草案）》及其摘要。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）及 指定媒体的《益方生物科技（上海）股份有限公司 2025 年限制性股票激励计划 （草案）摘要公告》（公告编号：2025-048）。 表决结果：同意 9 票；反对 0 票；弃权 0 票。 本议案已经公司董事会薪酬与考核委员会审议通过。 本议案尚需提交公司股东会审议。 一、董事会会议召开情况 益方生物科技（上海）股份有限公司（以下简称"公司"）第二届董事会 2025 年第九次会议于 2025 年 12 月 19 日以现场结合通讯形式召开，本 ...

益方生物科技（上海）股份有限公司董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划（草案）的核查意见 益方生物科技（上海）股份有限公司（以下简称"公司"）董事会薪酬与考核 委员会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《上海证券交易所科创板股票上市规则》《科创 板上市公司自律监管指南第4号——股权激励信息披露》等相关法律、法规及规范 性文件和《益方生物科技（上海）股份有限公司章程》的有关规定，对《公司 2025年限制性股票激励计划（草案）》（以下简称"《激励计划（草案）》"或 "本激励计划"）进行了核查，发表核查意见如下： 一、公司不存在法律、法规及《管理办法》规定的禁止实施股权激励计划的下 列情形： 1、最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法表示 意见的审计报告； 2、最近一个会计年度财务报告内部控制被注册会计师出具否定意见或无法表 示意见的审计报告； 3、上市后最近36个月内出现过未按法律法规、《公司章程》、公开承诺进行 利润分配的情形； 4 ...

Group 1 - The core viewpoint of the news highlights a significant increase in the Shanghai Stock Exchange's Sci-Tech Innovation Board Innovative Drug Index, with a rise of 3.26% as of December 19, 2025, driven by strong performances from constituent stocks such as Chengdu Xian Dao (up 10.44%) and Yifang Bio (up 9.82%) [1] - The recent announcement by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the 2025 National Basic Medical Insurance Drug List includes 114 new drugs, of which 50 are innovative drugs, marking an 88% success rate, a 12 percentage point increase from 2024 [3] - The total R&D investment by innovative drug companies on the Sci-Tech Innovation Board reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall level of A-shares [4] Group 2 - The collaboration between Innovent Biologics and Takeda Pharmaceutical regarding three innovative cancer drugs has been completed, with Innovent receiving a total upfront payment of $1.2 billion, including a strategic investment of $100 million, and potential milestone payments of up to $10.2 billion [5] - The CXO industry is entering a new high prosperity cycle, driven by external improvements, including overseas interest rate cuts and domestic recovery, with a focus on innovative drug companies benefiting from policy support and innovation upgrades [6] - The implementation of the "Medicare + Commercial Insurance" multi-layered medical security system is seen as a substantial breakthrough, with nearly 90% of new drugs approved by Sci-Tech Board biopharmaceutical companies included in the insurance list [3][4]

（文章来源：每日经济新闻） 每经AI快讯，12月19日，创新药概念震荡反弹，益方生物涨超10%，新诺威、维康药业、亚虹医药、阳 光诺和、悦康药业跟涨。 ...

Core Viewpoint - Yifang Bio has established licensing agreements for two products, indicating a strategic move to expand its market presence and collaboration with other pharmaceutical companies [2] Group 1: Licensing Agreements - The company has two externally licensed products, including Befotalimab, for which it has reached a licensing cooperation with Betta Pharmaceuticals in the regions of mainland China, Hong Kong, and Taiwan [2] - For the product D-1553 (Gosorese), the company has granted an exclusive license to Zhengda Tianqing for the development, registration, production, and commercialization in mainland China [2]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学制药板块主力资金净流出4.98亿元，游资资金净流入7193.04万元，散户资 金净流入4.26亿元。化学制药板块个股资金流向见下表： 证券之星消息，12月18日化学制药板块较上一交易日下跌0.04%，益方生物领跌。当日上证指数报收于 3876.37，上涨0.16%。深证成指报收于13053.98，下跌1.29%。化学制药板块个股涨跌见下表： ...

泓德医疗创新混合发起式A（012481）基金经理为操昭煦。 截至发稿，操昭煦累计任职时间4年350天，现任基金资产总规模1751.47万元，任职期间最佳基金回 报-10.36%， 任职期间最差基金回报-35.88%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室，成 立日期2013年1月11日，上市日期2022年7月25日，公司主营业务涉及创新药物的研发、生产和销售。主 营业务收入构成为：技术授权和技术合作收入100.00%。 从基金十大重仓股角度 数据显示，泓德基金旗下1只基金重仓益方生物。泓德医疗创新混合发起式A（012481）三季度持有股 数4.4万股，占基金净值比例为7.82%，位居第三大重仓股。根据测算，今日浮亏损失约6.6万元。 泓德医疗创新混合发起式A（012481）成立日期2023年2月22日，最新规模1480.31万。今年以来收益 35 ...

Group 1 - The autoimmune disease market is a blue ocean, with new targets and mechanisms driving rapid industry development. The global autoimmune market reached $132.3 billion in 2022 and is expected to grow to $176.7 billion by 2030, with a CAGR of 3.68% [2][3] - The drug development paradigm is shifting from broad-spectrum anti-inflammatory treatments to precision regulation, with significant room for improvement in efficacy and safety of existing drugs [2][3] Group 2 - Psoriasis affects approximately 125 million patients globally, with a focus on large molecule antibody drugs and a surge in small molecule oral TYK2 inhibitors that may replace existing treatments [3] - Atopic dermatitis impacts over 204 million people worldwide, with Dupilumab achieving sales exceeding $12.9 billion in the first three quarters of 2025, and new oral drugs like STAT6PROTAC showing superior efficacy [3] - The clinical demand for autoimmune diseases remains largely unmet, with domestic companies actively innovating in drug development, focusing on target innovation and expanding indications [4] Group 3 - Companies to watch include: 1. **Xiansheng Pharmaceutical**: Focused on differentiated targets with potential candidates like SIM0278, SIM0709, and SIM0711 [4] 2. **Kangnuo Pharmaceutical**: Rapidly increasing sales of Dupilumab, with peak sales expected to reach 5 billion yuan; CM512 shows promise as a leading TSLPxIL-13 dual antibody [4] 3. **Quansheng Biotechnology**: QX013N targets c-kit for CSU treatment, with additional dual antibody projects expected to submit IND applications between 2025 and 2026 [4] 4. **Yifang Biotechnology**: D-2570 (TYK2 inhibitor) is in Phase II clinical trials for UC, with promising Phase II data for psoriasis [4] 5. **Sanofi Genzyme**: Rapidly advancing IL-5 monoclonal antibody for asthma, with NDA submission expected by 2027 [4]

Core Insights - The incidence of acute gout is rising globally, particularly among younger populations aged 18-35, who account for nearly 60% of cases, with a significantly higher male-to-female ratio [1][5] - By 2024, the global number of acute gout patients is expected to reach 45.4 million, with China contributing approximately 19.4 million cases; this number is projected to increase to 47.7 million globally and 22.2 million in China by 2025 [1][5] - The global acute gout drug market is expected to stabilize around $1.5 billion by 2025, with China's market size estimated at $0.1 billion [1][5] Industry Definition and Classification - Gout is a type of crystal arthritis caused by purine metabolism disorders or reduced uric acid excretion, primarily characterized by the deposition of monosodium urate crystals [2][3] - Treatment options are categorized into two main types: drugs for acute gout attacks and uric acid-lowering drugs [3][4] Current Industry Status - The acute gout drug market has remained stable despite rising patient numbers due to price increases leading to decreased sales volume [5] - The need for effective treatment is critical as uncontrolled acute attacks can lead to increased frequency and severity, impacting patients' quality of life [5] Industry Chain - The upstream of the acute gout drug industry includes raw materials, intermediates, and production equipment; the midstream focuses on drug R&D and production, while the downstream involves distribution channels and end patients [6] Regulatory Environment - The Chinese government has been enhancing policy guidance and regulation in the acute gout drug industry through various healthcare and drug management policies to promote healthy industry development [6] Competitive Landscape - Major competitors in the acute gout drug market include companies like Haichuang Pharmaceutical, Heng Rui Medicine, Yifang Bio, and Yipinhong, which are actively developing clinical pipelines for hyperuricemia and gout treatments [7][8] - The market is characterized by a strong demand for new, safe uric acid-lowering drugs, as existing treatments do not fully meet clinical needs [7] Development Trends - The acute gout drug industry in China is rapidly evolving, with market expansion and increasing competition driven by policy support, technological advancements, and market demand [10] - The industry is moving towards more precise, effective, and personalized treatment options, with a focus on domestic alternatives to improve patient outcomes [10]